PPD Expands GMP Lab Services
By

By
Pharmaceutical Product Development (PPD), a contract research organization headquartered in Wilmington, North Carolina, has expanded its GMP laboratory operations in Athlone, Ireland. The lab has added 400 square meters (4,300…

Patheon, Biophytis in Manufacturing Pact for Eye Drug
By

By
Biophytis, a Romainville, France-based biotechnology company, has formed an agreement with Patheon for the industrial scale-up manufacturing of clinical batches for macuneos, a drug candidate for the dry form of…

Marken Opens Operations in Brisbane, Australia
By

By
Marken, a Research Triangle Park, North Carolina-based provider of clinical trial materials and logistics services, has opened a new office in Brisbane, Australia to strengthen its Australian operations and will support…

Hermes Launches New Desiccant Stopper
By

By
Hermes Pharma, a Pullach, Germany-based producer of  oral dosage forms, has launched a new desiccant stopper suitable for multi-dose tablet tube containers. With an improved finger-mold grip, the stopper can…

Bespak Launches Auto-Injector for Viscous Drug Formulations
By

By
Bespak, a Cambridge, UK-based drug delivery firm and a Consort Medical company, has launched its Syrina AR 2.25 auto‑injector for viscous drug formulations. It delivers volumes of up to 2…

KemPharm Licenses Acura’s Drug-Abuse Deterrent Technology
By

By
KemPharm, a Coraville, Iowa-based clinical-stage specialty pharmaceutical company, has entered into a license agreement with Acura Pharmaceuticals, a Palatine, Illinois-based pharmaceutical company, for Acura to provide its proprietary Aversion technology…

IDT Biologika Wins US Gov’t Contract for Fill/Finish
By

By
IDT Biologika, a Dessau, Germany-based manufacturer of vaccines and biopharmaceuticals, has won a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the office of the Assistant for…

Lonza in Pact for Immuno-Oncology Antibody Pipeline
By

By
Lonza has entered into a manufacturing agreement with Forty Seven, a Palo Alto, California-based clinical-stage immuno-oncology company, for the clinical supply of Forty Seven’s therapeutic antibodies. Under the agreement Lonza…

Catalent Breaks Ground for Expanded Biologics Facility
By

By
Catalent Pharma Solutions has broken ground for a new $34-million extension to its Madison, Wisconsin biologics manufacturing facility. When completed, the additional 22,000 square feet of space will accommodate a…

Samsung Bioepis, Catalent in Supply Pact for Enbrel Biosimilar
By

By
Catalent Pharma Solutions has agreed to provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Amgen’s anti-inflammatory product, Enbrel (etanercept), on behalf of Samsung Bioepis, the…